Search

Xenon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

39.04 0.51

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

37.86

Massimo

39.35

Metriche Chiave

By Trading Economics

Entrata

-8.4M

-111M

EPS

-1.11

Dipendenti

358

EBITDA

420K

-111M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+83.17% upside

Dividendi

By Acuity

Utili prossimi

2 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2.2B

3.8B

Apertura precedente

38.53

Chiusura precedente

39.04

Notizie sul Sentiment di mercato

By Acuity

75%

25%

295 / 339 Classifica in Healthcare

Xenon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 set 2026, 20:07 UTC

News

Xenon Pharmaceuticals Inc is advancing slightly higher, following its announcement to present at the TD Cowen Summit on September 23, 2026.

21 set 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares fell amid analyst target cuts, with Baird lowering its target to $90 and Needham reducing it to $60, while enrollment in trials is paused.

18 set 2026, 23:06 UTC

Xenon Pharmaceuticals Inc is up in after-market trading, buoyed by broader market trends despite ongoing concerns over industrial sector weakness and rising Treasury yields.

17 set 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

16 set 2026, 20:10 UTC

Xenon Pharmaceuticals Inc is advancing modestly in Wednesday's market session, despite earlier pulling back from a session high amid a broadly lower market.

15 set 2026, 20:02 UTC

Xenon Pharmaceuticals shares are lower amid broader market declines linked to a significant drop in the NY Empire State Manufacturing Index for September.

14 set 2026, 22:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, recovering from recent declines despite remaining below the 20-day moving average. No specific news was identified.

11 set 2026, 20:08 UTC

Xenon Pharmaceuticals Inc shares are lower, marking six consecutive sessions of declines. Broader market sentiment may be affected by a rise in the Consumer Price Index.

9 set 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares are lower today, marking the fourth consecutive session of declines, with no specific news identified for the drop.

8 set 2026, 20:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours amid a broader market decline, with no specific company news identified for the drop.

4 set 2026, 23:40 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite no specific company news, amid broader macroeconomic influences.

1 set 2026, 20:09 UTC

News

Xenon Pharmaceuticals shares are lower as negative sentiment follows an insider sale of 7,068 shares by Chief Medical Officer Kenney Christopher John.

31 ago 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting an upward move since Monday's close amid broader market expectations for interest rate hikes.

28 ago 2026, 20:02 UTC

News

Xenon Pharmaceuticals shares are lower as the company presented Phase 3 data on azetukalner at the European Epilepsy Congress, amid market volatility.

27 ago 2026, 20:02 UTC

Social Media
Event
News

Xenon Pharmaceuticals will present Phase 3 X-TOLE2 trial data at an epilepsy meeting. Shares are lower despite recent announcements regarding upcoming presentations.

26 ago 2026, 21:51 UTC

News

Xenon Pharmaceuticals will present data on azetukalner at the European Epilepsy Congress in September 2026, contributing to shares moving higher in after-market hours.

24 ago 2026, 19:56 UTC

Xenon Pharmaceuticals Inc shares are lower today, reflecting ongoing market weakness. The stock is near the lower end of its one-month range.

21 ago 2026, 23:51 UTC

Xenon Pharmaceuticals shares are lower in after-market trading, reflecting challenges in maintaining upward momentum and positioning below the 20-day moving average.

20 ago 2026, 22:51 UTC

Shares of Xenon Pharmaceuticals are lower in after-market trading, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

19 ago 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is higher in after-market trading, rebounding from an initial dip and reflecting strength despite no specific news to explain the movement.

18 ago 2026, 19:26 UTC

Xenon Pharmaceuticals is trading higher today, reflecting cumulative gains since Monday, though it remains below its 20-day moving average.

17 ago 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15 ago 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14 ago 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13 ago 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12 ago 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 ago 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 ago 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

Confronto tra pari

Modifica del prezzo

Xenon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

83.17% in crescita

Previsioni per 12 mesi

Media 71.417 USD  83.17%

Alto 90 USD

Basso 46 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Xenon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

15

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

295 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.